Results 281 to 290 of about 83,254 (357)

Molecular characterisation of ret tyrosine kinase signalling [PDF]

, 2005
Arighi, Elena
core  

No Increased Risk of Thromboembolic Events During 6‐Month Treatment With Baricitinib in Patients With Alopecia Areata

International Journal of Dermatology, EarlyView.
Giacomo Caldarola, Antonietta Ferretti, Lorenzo Maria Pinto, Leonardo Di Gennaro, Eleonora De Luca, Gennaro Marco Falco, Clara De Simone, Raimondo De Cristofaro, Ketty Peris   +8 more
wiley   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Earlier onset of acute venous thromboembolism with upadacitinib compared with tofacitinib during Janus kinase inhibitor therapy. [PDF]

Res Pract Thromb Haemost
Lowell JA, Sharma G, Sultan K.
europepmc   +1 more source

Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort

International Journal of Dermatology, EarlyView.
Alonso García‐Núñez, Antonio Alcalá Ramírez Del Puerto, Roberto Daza‐García, María Teresa Monserrat‐García, Mercedes Morillo‐Andújar, Javier Jesús Domínguez‐Cruz, Román Barabash‐Neila   +6 more
wiley   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source

Mycophenolate Mofetil, an Inhibitor of Inosine Monophosphate Dehydrogenase, and Tofacitinib, a Janus Kinase Inhibitor, Attenuate Airway Inflammation and Hyperresponsiveness in a Mouse Model of Allergic Asthma. [PDF]

Molecules
Kravčenia B, Maślanka T.
europepmc   +1 more source

Psychosine Alleviates Colitis via Inhibiting Th1 and Th17 Cell Immune Responses in Inflammatory Bowel Diseases

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background Aberrant T‐helper 1 (Th1) and Th17 cell activation is involved in the pathogenesis of inflammatory bowel disease (IBD). Psychosine is known to induce apoptosis, promote astrocyte activation, and inhibit osteoclastogenesis. However, the role of psychosine on Th1 and Th17 cell immune responses has not been previously reported. In this
Ritian Lin, Jiayi Tu, Shan Li, Qinjuan Sun, Lan Zhong   +4 more
wiley   +1 more source

The “Reducing Inflammation for Greater Health Trial (RIGHT)” Study—Concept, Rationale, and Design

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT The Reducing Inflammation for Greater Health Trial's (RIGHT) study is a single‐center, randomized, double‐blind, placebo‐controlled trial designed to test whether clazkizumab, an interleukin‐6 (IL‐6) inhibitor, can improve or slow decline in physical, cognitive, and vascular function in older adults, when compared to a placebo.
Sebastian E. Sattui, Marnie Bertolet, Daniel E. Forman, Michelle E. Danielson, Shanshan Yao, Oscar L. Lopez, Nancy W. Glynn, Neelesh K. Nadkarni, Akira Sekikawa, Tullia C. Bruno, Toren Finkel, Anne B. Newman   +11 more
wiley   +1 more source